Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 110   

Articles published

SHP 5,052.50 +12.50 (0.25%)
price chart
Shire PLC 23.2% Potential Upside Indicated by JP Morgan Cazenove
Shire PLC using EPIC/TICKER code LON:SHP has had its stock rating noted as 'Reiterates' with the recommendation being set at 'OVERWEIGHT' this morning by analysts at JP Morgan Cazenove.
Will Shire PLC (ADR) (SHPG) Move with Raptor Pharmaceutical Corp. (RPTP)?
The acquisition of the Raptor will help Shire to make its amino acid Cystine in relation to the Quinsair for kidney failure patients.
Shire Plc (NASDAQ:SHPG) Updated Price Targets  FTSE News
Jennison Associates LLC Increased Shire Plc (NASDAQ:SHPG) by $22.10 Million ...  Press Telegraph
Shire PLC's (SHP) "Overweight" Rating Reaffirmed at JPMorgan Chase & Co.
Shire PLC logo JPMorgan Chase & Co. reissued their overweight rating on shares of Shire PLC (LON:SHP) in a report released on Tuesday morning.
JP Morgan Indicates Potential 23.65% Increase In Shares Of Shire PLC  Fiscal Standard
JP Morgan Cazenove Reconfirmed Shire PLC (LON:SHP) As Overweight; Has PT Of ...  Press Telegraph
JP Morgan Reiterated Shire PLC (LON:SHP) As 'Overweight'
Following JP Morgan's latest price target of 6300 on the business this highlights that the broker now believes there is an increase of 23.29% from Shire PLC's current share price of 5110. The number of shares Shire PLC currently has in issue is 682,799 ...
Shire PLC 24.8% Potential Upside Indicated by Cantor Fitzgerald
Shire PLC using EPIC/TICKER code LON:SHP had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Cantor Fitzgerald.
Shire PLC's (SHP) Outperform Rating Reiterated at BNP Paribas  The Cerbat Gem
Cantor Fitzgerald Gives Shire PLC Price Target With Potential 25.25% Upside  FTSE News
Shire PLC 22.8% Potential Upside Indicated by JP Morgan Cazenove
Shire PLC with EPIC/TICKER LON:SHP has had its stock rating noted as 'Reiterates' with the recommendation being set at 'OVERWEIGHT' this morning by analysts at JP Morgan Cazenove.
Shire PLC (SHP) Receives "Overweight" Rating from JPMorgan Chase ...  Community Financial News
Shire PLC Lags GlaxoSmithKline plc, AstraZeneca plc, Pfizer Inc. And Johnson ...
Pharmaceutical company Shire PLC (LON: SHP) (LSE: SHP.L) has fallen by 0.9% today following the release of its six-month results to the end of June 2016.
Shire: New Acquisition
The company has a well-diversified portfolio, but having this focus will enable them to prosper. Over the year, Shire has shifted it's rare disease revenue stream from 45% to 65% of total revenue, due to the Baxalta merger.
Keep track of Analyst's Recommendation: Ophthotech Corporation (NASDAQ:OPHT ...
Shire plc (NASDAQ:SHPG) finished the trade at $199.82, higher +0.61%. Its last's traded volume was 497.28 thousand shares in comparison to its average trading volume of 2.4 million shares.
Shire plc (SHPG) Tops Q2 EPS by 35c; Guides FY16 EPS Above Views
Shire plc (NASDAQ: SHPG) reported Q2 EPS of $3.38, $0.35 better than the analyst estimate of $3.03. Revenue for the quarter came in at $2.43 million versus the consensus estimate of $2.22 million.
Should Shareholders Heed Shire PLC (NASDAQ:SHPG)'s Advice?  Market Exclusive
Shire plc (NASDAQ:SHPG) topped earnings-per-share estimates 83% of the time  Zergwatch